NN111: ExTINGUISH
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is an interventional, randomized control, clinical trial involving inebilizumab (investigational drug, given only at two timepoints by infusion) in patients with anti-NMDA receptor encephalitis. The purpose is to determine the difference in modified Rankin score at 16 weeks in participants with anti-NMDA receptor encephalitis treated with 'first-line' immunomodulatory therapies given as standard of care OR inebilizumab. It involves 16 study visits over the course of 96 weeks.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 850466
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
